Loading
Life sciences · Journal article
Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as one of the most common causes of chronic liver disease worldwide. The increasing prevalence of obesity, diabetes mellitus, sedentary lifestyle, and unhealthy dietary patterns has contributed to the growing burden of MAFLD in Bangladesh. The disease is strongly associated with insulin resistance, metabolic syndrome, cardiovascular disease, and progressive liver fibrosis. Objective: This abstract aims to summarize the current understanding of MAFLD, focusing on epidemiology, risk factors, diagnostic approaches, and management perspectives in Bangladesh. Methods: A narrative review was conducted based on available epidemiological studies, clinical evidence, and updated recommendations regarding MAFLD in Bangladesh and globally. Results: The global prevalence of MAFLD has increased to more than 30%, with 10–30% of affected individuals developing metabolic dysfunction-associated steatohepatitis (MASH). Bangladesh represents a high-burden region, with a reported MAFLD prevalence of 33.86%. Overweight, obesity, and diabetes are major contributors, with obese individuals showing substantially increased odds of MAFLD development. A significant proportion of Bangladeshi patients demonstrate progressive disease, with 42.4% of biopsy-confirmed fatty liver disease patients showing definitive MASH. Emerging evidence also highlights the presence of lean MAFLD and lean MASH, demonstrating that the disease is not restricted to obese individuals. Diagnosis relies on assessment of hepatic steatosis, metabolic risk factors, and non-invasive fibrosis evaluation tools such as Fibrosis-4 (FIB-4) index, vibration-controlled transient elastography, and other fibrosis markers. Lifestyle modification, including dietary optimization, weight reduction, and regular physical activity, remains the cornerstone of management. Recent targeted therapeutic approaches, including resmetirom and semaglutide, have shown promising roles in improving MASH resolution, fibrosis outcomes, metabolic control, and overall disease management. Conclusion: MAFLD is an increasing public health challenge in Bangladesh. Early identification of high-risk individuals, appropriate fibrosis assessment, lifestyle intervention, and multidisciplinary management are essential to reduce disease progression and liver-related complications. Integration of emerging targeted therapies with preventive strategies may provide new opportunities for improving outcomes among patients with progressive MAFLD. [J Assoc Clin Endocrinol Diabetol Bangladesh, 2026;5 (Suppl 1): S2]